Cargando...
Targeting neoplastic B cells and harnessing microenvironment: the “double face” of ibrutinib and idelalisib
Tyrosine kinase inhibitors (TKIs) targeting signaling molecules downstream B cell receptor (BCR) are powerfully spreading in the therapeutic landscape of B cell lymphoproliferative disease, due to a manageable toxicity profile and encouraging clinical effectiveness. In particular, ibrutinib, previou...
Gardado en:
| Publicado en: | J Hematol Oncol |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
BioMed Central
2015
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4459446/ https://ncbi.nlm.nih.gov/pubmed/26022368 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-015-0157-x |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|